Physician profile
Heather Mott
NPI 1568707370
$3,150.20
in general payments reported to CMS, 2019-2025
16 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $1,619 · 2023: $497 · 2024: $484 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,067.37 | 2021-2025 | |
| Neuronetics, INC. | $992.60 | 2022-2025 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $403.55 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $170.39 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $89.75 | 2021-2024 | Austedo, Austedo Xr |
| Lundbeck LLC | $63.80 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $59.38 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $56.08 | 2024-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $53.24 | 2022 | |
| Janssen Pharmaceuticals, INC | $47.86 | 2021-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $47.83 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $36.89 | 2021 | |
| Indivior INC. | $16.69 | 2021 | |
| Tris Pharma INC | $16.20 | 2025 | Dyanavel Xr |
| Brainsway USA INC | $14.51 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Mott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.